Long-acting injectable atovaquone nanomedicines for malaria prophylaxis

Rahul P. Bakshi, Lee M. Tatham, Alison C. Savage, Abhai K. Tripathi, Godfree Mlambo, Matthew M. Ippolito, Elizabeth Nenortas, Steve P. Rannard, Andrew Owen, Theresa A. Shapiro

Research output: Contribution to journalArticlepeer-review

31 Scopus citations


Chemoprophylaxis is currently the best available prevention from malaria, but its efficacy is compromised by non-adherence to medication. Here we develop a long-acting injectable formulation of atovaquone solid drug nanoparticles that confers long-lived prophylaxis against Plasmodium berghei ANKA malaria in C57BL/6 mice. Protection is obtained at plasma concentrations above 200 ng ml-1 and is causal, attributable to drug activity against liver stage parasites. Parasites that appear after subtherapeutic doses remain atovaquone-sensitive. Pharmacokinetic-pharmacodynamic analysis indicates protection can translate to humans at clinically achievable and safe drug concentrations, potentially offering protection for at least 1 month after a single administration. These findings support the use of long-acting injectable formulations as a new approach for malaria prophylaxis in travellers and for malaria control in the field.

Original languageEnglish (US)
Article number315
JournalNature communications
Issue number1
StatePublished - Dec 1 2018

ASJC Scopus subject areas

  • Chemistry(all)
  • Biochemistry, Genetics and Molecular Biology(all)
  • Physics and Astronomy(all)


Dive into the research topics of 'Long-acting injectable atovaquone nanomedicines for malaria prophylaxis'. Together they form a unique fingerprint.

Cite this